Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics reported a robust revenue growth of over 40% in 2024, exceeding RMB8.2 billion, largely driven by its strong position in oncology and the successful launch of new products. Looking forward to 2025, the company plans to introduce six new drugs, including three novel oncology treatments, and capitalize on opportunities in chronic diseases. With its advancements in R&D and strategic market positioning, Innovent is confident in achieving its revenue target of RMB20 billion by 2027 and aims to continue its trajectory of sustainable growth and global innovation.
More about Innovent Biologics
Innovent Biologics, Inc., incorporated in the Cayman Islands, is a leading biopharmaceutical company specializing in oncology and general biomedicine. The company is known for its innovative drugs and has a strong presence in the field of immuno-oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. Innovent is focused on expanding its product portfolio and enhancing its market presence, particularly in the Chinese market.
YTD Price Performance: -3.93%
Average Trading Volume: 34,803
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.95B
Learn more about 1801 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue